登录注册

Tumor immune microenvironment remodeling predicts response to checkpoint inhibitor therapy

Cancer Cell

Lin et al. assemble a longitudinal pan-cancer single-cell atlas that tracks how the tumor immune microenvironment remodels during checkpoint inhibitor therapy. They show that the direction of remodeling, rather than the pre-treatment state, predicts response and translate these dynamics into a baseline gene signature that forecasts outcome across cancer types.

Related products

Catalog No.	Product Name	Description	Target
HS870036	Research Grade Balstilimab (Anti-PD-1)	Balstilimab (HS870036) is a research-grade recombinant antibody targeting CD1. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.	Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1, CD279

7X24小时产品咨询热线：027--87433958(9:00-18:00)，或扫描下方产品专员二维码或在线留言
武汉东湖新技术开发区神墩四路666号研发楼B区3层东

24小时产品查询
扫一扫关注我们
专属渠道经理

鄂ICP备2023002448号-2

重组蛋白

抗体

试剂盒

实验相关试剂

Tumor immune microenvironment remodeling predicts response to checkpoint inhibitor therapy